Ryan Lutz

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

Rajesh Krishna, Matt S. Anderson, Arthur Bergman et al. · The Lancet · 2007 · 277 citations

Life Sciences, Pharmacology, Pharmacotherapy +15

Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A

Thomayant Prueksaritanont, DA Tatosian, Xiaoyan Chu et al. · Clinical Pharmacology & Therapeutics · 2016 · 139 citations

Medicine, Pharmacokinetics, Pharmacology +14

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

Rajesh Krishna, AJ Bergman, Bo Jin et al. · Clinical Pharmacology & Therapeutics · 2008 · 100 citations

Life Sciences, Pharmacokinetics, Pharmacology +16

Single‐dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

Rajesh Krishna, Amit Garg, Deborah Panebianco et al. · British Journal of Clinical Pharmacology · 2009 · 51 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +9

Carboxylesterase catalyzed 18O-labeling of carboxylic acid and its potential application in LC-MS/MS based quantification of drug metabolites

Zaikuan Yu, Joseph M. Roesner, Ryan Lutz et al. · Drug Metabolism and Pharmacokinetics · 2019 · 10 citations

Life Sciences, Biochemistry, Chemistry +16